To date, several sartan drugs have had to be recalled due to the presence of unacceptable levels of nitrosamines – a group of organic compounds of which many are either known or suspected to be carcinogenic. To prevent the recurrence of such events, it is paramount that drug manufacturers have powerful tools at their disposal for analyzing nitrosamine impurities, to ensure levels remain below regulatory limits.
In this app note, discover a comprehensive solution that can:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2020 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy